Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost. Issue 2 (31st October 2022)
- Record Type:
- Journal Article
- Title:
- Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost. Issue 2 (31st October 2022)
- Main Title:
- Injectable Polymer‐Nanoparticle Hydrogel for the Sustained Intravitreal Delivery of Bimatoprost
- Authors:
- Meany, Emily L.
Andaya, Roxanne
Tang, Shijia
Kasse, Catherine M.
Fuji, Reina N.
Grosskopf, Abigail K.
d'Aquino, Andrea L.
Bartoe, Joshua T.
Ybarra, Ryan
Shelton, Amy
Pederson, Zachary
Hu, Chloe
Leung, Dennis
Nagapudi, Karthik
Ubhayakar, Savita
Wright, Matthew
Yen, Chun‐Wan
Appel, Eric A. - Abstract:
- Abstract: Vision impairment resulting from chronic eye diseases, such as macular degeneration and glaucoma, severely impacts patients' quality of life and poses an immense global financial burden. Current standard of care for such diseases includes daily eye drops or frequent intravitreal (ITV) injections, which are burdensome treatment modalities resulting in low patient compliance. There remains a growing need for easily administered long‐acting delivery technologies for prolonging exposure of ocular therapeutics with each administration. Here, this work deploys a supramolecular polymer‐nanoparticle (PNP) hydrogel for ITV delivery of the glaucoma drug bimatoprost. PNP hydrogels are shear‐thinning and self‐healing, key properties for injectability, and enable slow release of molecular cargo in vitreous humor (VH) mimics. An in vivo study in New Zealand white rabbits demonstrated intravitreally injected PNP hydrogels form depots that degrade slowly over time, maintaining detectable levels of bimatoprost in the VH up to 8 weeks following injection. Ophthalmic examinations and histopathology identified a mild foreign body response (FBR) to the hydrogel, characterized by rare clusters of foamy macrophages and giant cells associated with minimal, patchy fibroplasia. This work shows that PNP hydrogels exhibit numerous desirable traits for sustained drug delivery and further work will be necessary to optimize tolerability in the eye. Abstract : Here, this work evaluatesAbstract: Vision impairment resulting from chronic eye diseases, such as macular degeneration and glaucoma, severely impacts patients' quality of life and poses an immense global financial burden. Current standard of care for such diseases includes daily eye drops or frequent intravitreal (ITV) injections, which are burdensome treatment modalities resulting in low patient compliance. There remains a growing need for easily administered long‐acting delivery technologies for prolonging exposure of ocular therapeutics with each administration. Here, this work deploys a supramolecular polymer‐nanoparticle (PNP) hydrogel for ITV delivery of the glaucoma drug bimatoprost. PNP hydrogels are shear‐thinning and self‐healing, key properties for injectability, and enable slow release of molecular cargo in vitreous humor (VH) mimics. An in vivo study in New Zealand white rabbits demonstrated intravitreally injected PNP hydrogels form depots that degrade slowly over time, maintaining detectable levels of bimatoprost in the VH up to 8 weeks following injection. Ophthalmic examinations and histopathology identified a mild foreign body response (FBR) to the hydrogel, characterized by rare clusters of foamy macrophages and giant cells associated with minimal, patchy fibroplasia. This work shows that PNP hydrogels exhibit numerous desirable traits for sustained drug delivery and further work will be necessary to optimize tolerability in the eye. Abstract : Here, this work evaluates polymer‐nanoparticle (PNP) hydrogels as long‐acting delivery vehicles following intravitreal injection. These materials prolong the retention and delivery of model cargo and glaucoma drug bimatoprost following injection into model vitreous humor (VH) in vitro and maintain detectable levels of bimatoprost in rabbits for up to 8 weeks following intravitreal administration. … (more)
- Is Part Of:
- Advanced therapeutics. Volume 6:Issue 2(2023)
- Journal:
- Advanced therapeutics
- Issue:
- Volume 6:Issue 2(2023)
- Issue Display:
- Volume 6, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 6
- Issue:
- 2
- Issue Sort Value:
- 2023-0006-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-10-31
- Subjects:
- biocompatibility -- drug delivery -- hydrogel -- intravitreal -- ophthalmology -- sustained delivery
Therapeutics -- Periodicals
Pharmaceutical technology -- Periodicals
Pharmacogenetics -- Periodicals
615.5 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/23663987 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/adtp.202200207 ↗
- Languages:
- English
- ISSNs:
- 2366-3987
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0696.935580
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25973.xml